The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Regular insulin, which is often used in pregnancy ... At present no reports on glulisine use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo ... without any prescriber intervention like a regular generic drug. Civica's move has been welcomed ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Insulin resistance is a growing issue that can lead to type 2 diabetes if not addressed in time. Fortunately, there are lifestyle changes that can improve this situation.

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Insulin-like growth factor (IGF) 1 is a member of a family that is involved in growth, development, cell differentiation, and metabolism. IGF1, IGF2 and insulin act primarily through tyrosine ...

Sliding scale insulin therapy involves following a chart of insulin dosages. A doctor will help a person with diabetes create this chart based on factors like how their body responds to insulin ...

Intermittent fasting can also positively affect the circadian rhythms of gut biology and the release of insulin and growth hormone. In this way, it can improve energy metabolism and weight regulation.

A polygon is a closed 2D shape with straight sides that meet at vertices. Polygons can be regular or irregular. If all the straight sides of a shape are the same length and interior angles are the ...

As you age, your risk for higher blood sugar increases—which raises the risk of type 2 diabetes for adults in their 50s, 60s, and 70s. Using a chart of blood sugar levels by age can help you track ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.